Comparative Pharmacology
Head-to-head clinical analysis: BRONKODYL versus XOPENEX HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKODYL versus XOPENEX HFA.
BRONKODYL vs XOPENEX HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP via activation of adenylyl cyclase.
Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/mL.
2 inhalations (90 mcg each) every 4-6 hours as needed via oral inhalation. Maximum 12 inhalations per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 3–8 hours in non-smoking adults, 1–5 hours in smokers, and 20–30 hours in premature neonates; clinical context: half-life increases in hepatic impairment, heart failure, and with certain medications (e.g., cimetidine, fluoroquinolones).
Terminal elimination half-life: 3-4 hours; clinical context: dosing every 4-6 hours for bronchodilation
Renal: approximately 90% as theophylline and its metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid); biliary/fecal: <10%.
Renal: 80-100% as unchanged drug and metabolites; fecal: minimal (<5%)
Category C
Category C
Bronchodilator
Bronchodilator